Stock jumped 21% on “next-gen” news

Could we see another push higher today 🤔

August 28, 2025

The wellness space just keeps getting weirder and more interesting. Stem cells, gene-level supplements… a company out of Singapore is stepping into the mix. Its stock is sitting in a spot where things could get interesting…

TODAY’S TOP ALERT! 

EUDA Health Holdings (Nasdaq: EUDA)

👉  EUDA is TODAY’S #1 ALERT 👈

Good morning, Folks,

NVDA shares are down in the pre-market this morning after their stellar earnings failed to impress investors.

Top analysts are impressed, though, and are raising their price targets. J.P. Morgan lifted its price target to $215 from $170, and Morgan Stanley bumped its target to $210 from $206.

I hope we can all agree my “tactical trade” idea from yesterday was impressive:

My “tactical” idea for today is an interesting one.

It’s a company based in Singapore that is well diversified in the wellness industry, and that recently branched into stem cell therapy.

That’s still controversial in the US, of course, but many people — including the likes of Joe Rogan — sing its praises.

Go ahead and pull up EUDA Health Holdings Limited (EUDA) and check out the setup.

Now, I want to start with a word of caution: this is a highly volatile trading stock. 

EUDA is a new one to me, and while the chart suggests it could see a bounce very soon, always have a well-thought-out game plan before you make any trade (with this or anything else!), and stick to your plan.

The stock traded within a stable range for much of the year, but in June, it filed an at-the-market offering agreement, and the stock dropped on dilution concerns.

In August, it filed a convertible promissory note purchase agreement, and that has pulled the stock down further.

On Tuesday, however, the company released only its second press release of the year, revealing it had secured worldwide rights to a “next-generation immune health supplement.”

The stock hit 21% intraday on the news but fell back down into the close.

I’m wondering if that was due to profit-taking and if we’ll see another runup today, especially after they just announced a major potential acquisition.

According to what I read, EUDA gains a 120-day exclusivity window to explore the acquisition and deepen its foothold in molecular supplements and gene-modulating formulations. 

I’ll discuss more below, but EUDA already appears to hold global distribution rights to Chemokine’s next‑gen immune health product, Euda Helixé.

Tune into EUDA to find out!

👉  EUDA is TODAY’S #1 ALERT 👈

EUDA was founded in 2019 and is headquartered in Singapore.

It describes itself as a “property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia.”

It aims to “transform the health and wellness landscape by leveraging cutting-edge technology to enhance non-invasive treatments and expand holistic healthcare access in Southeast Asia.”

In May 2024, the company acquired CK Health Plus in Malaysia, gaining access to CK’s “distribution network, customer base, and expertise in the wellness industry.”

That gave EUDA exclusive distribution rights in Malaysia, Vietnam, and Indonesia to a whole range of holistic wellness products, including bioenergy cabins (details on those, including video, here), collagen drinks, supplements, and skincare products.

EUDA said it planned to “license bioenergy cabins to partners such as spas, beauty salons, and confinement centers” and to distribute consumer products “through direct selling, e-commerce platforms, and retail outlets.”

That led to a months-long runup of EUDA’s stock price, peaking in December 2024 nearly 250% higher than before its May announcement.

Also last December, the company began exploring a potential partnership with Guangdong Cell Biotech, a “prominent player in stem cell therapies and regenerative medicine.”

Those talks culminated in April of this year with a commercial distribution arrangement whereby CK Health would “market and sell to EUDA customers in Singapore and Malaysia stem cell therapies provided by Guangdong Cell Biotech in China.”

Here is a page on EUDA’s website describing the stem cell therapies, which includes a link to this English presentation that covers them.

The company’s only other press release in 2025 is this one from just this Tuesday announcing it secured “exclusive worldwide distribution rights for a next-generation immune health supplement … from Chemokine Pte. Ltd. … a Singapore-based biotech company focused on molecular supplements and gene modulating formulations.”

The company plans to market the supplement under its brand name, Euda Helixé, “initially in Singapore, Malaysia, and China before expanding it to other markets in the future.”

It says the supplement is “an advanced formulation designed to modulate gene expression by activating beneficial genes while silencing harmful ones” and says it “enhances metabolism, boosts vitality, [and] supports longevity.”

As you do your own research on EUDA, be sure to review the company website. Pay special attention to its SEC filings.

And of course, always approach your trading in a responsible manner,  remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Primetime Media for advertising EUDA Health Holdings Ltd for a one day marketing program starting on August 28, 2025. It might seem obvious, but while our client claims not to own any shares in EUDA Health Holdings Ltd, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into EUDA Health Holdings Ltd might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.